Austedo XR (Deutetrabenazine) Patent Expiration, LOE Window & CMS Spending

Austedo XR (Deutetrabenazine) by Teva Pharmaceuticals: FDA Orange Book core substance LOE 2034-03-18 (last listed 2041-06-10), 0 AB generics, $750.0M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTeva Pharmaceuticals
FDA Application & PathwayN216354 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2034-03-18
Last Listed Patent or Exclusivity Date2041-06-10
Orange Book Patents (*PED Extensions)23 patents (10 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$750.0M
2024 Medicare Part D Spend$597.2M
2024 Medicaid Spend$152.9M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Teva Pharmaceuticals across sibling Meru public-data platforms.